Objective: To determine the prevalence of clinical polycystic ovary syndrome (PCOS) in 14- to 18-year-old high school girls in Isfahan, Iran. Methods: In this cross-sectional study, 1,000 high school girls (14–18 years old) were selected by multi-stage random sampling from different high schools in Isfahan. Following physical examination, a single physician recorded the presence of hirsutism, severe acne, androgenic alopecia, menstrual dysfunction and obesity using a validated questionnaire. Clinical PCOS was diagnosed if menstrual dysfunction and clinical hyperandrogenism were detected. Results: Clinical PCOS was present in 30 (3%), hirsutism in 60 (6%), menstrual dysfunction in 74 (7.4%) and severe acne in 47 (4.7%) of the population studied. Conclusion: The prevalence of clinical PCOS in our study population was similar to those of other studies; however, the prevalence could have been higher with hormonal assessment.

1.
Dunaif A, Givens Jr, Haseltine FP, Marriam GR: Polycystic Ovary Syndrome. Current Issues in Endocrinology and Metabolism. Boston, Blackwell, 1992.
2.
Solomon CG: The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks. Endocrinol Metab Clin North Am 1999;28:247–263.
3.
Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R: Prevalence of the polycystic ovary syndrome in unselected black, and white women of the southeastern United States: A prospective study. J Clin Endocrinol Metab 1998;83:3078–3082.
4.
Gordon CM: Menstrual disorders in adolescents, excess androgens and the polycystic ovary syndrome. Pediatr Clin North Am 1999;46:519–545.
5.
Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:12–25.
6.
Ehrmann DA, Berner RB, Rosenfeile RH: Hyperandrogenism, hirsutism and polycystic ovary syndrome; in De Groot LJ, Jameson JL (eds): Endocrinology. Philadelphia, Saunders, 2001, vol 3, pp 2122–2137.
7.
Dermatologic disorders; in Beers HM, Berkow R (eds): The Merck Manual of Diagnosis and Therapy, ed 17. Whitehouse Station, Merck Research Laboratories, 1999.
8.
Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF: A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434–2438.
9.
Hetch R, Rosenfield RH, Kim MH, Trendway D: Hirsutism: Implications, etiology and management. Am J Obstet Gynecol 1981;140:815–830.
10.
Hammer LD, Kraemer HC, Wilson DM, et al: Standandized percentile curve of BMI for children and adolescents. Am J Dis Child 1991;145:259–263.
11.
Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al: A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006–4011.
12.
Van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J: Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteinzing hormone, androgens, and insulin. Fertil Steril 2000;74:49–58.
13.
Gordon CM: Menstrual disorders in adolescents. Excess androgens and the polycystic ovary syndrome. Pediatr Clin North Am 1999;46:519–543.
14.
Avvad CK, Holeuwerger R, Silva VC, Bordallo MA, Breitenbach MM: Menstrual irregularity in the first postmenarchal years: An early clinical sign of polycystic ovary syndrome in adolescence. Gynecol Endocrinol 2001;170–177.
15.
Van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J: Endocrine features of polycystic ovary syndrome in a random population sample of 14–16 year old adolescents. Hum Reprod 1999;14:2223–2229.
16.
Allen SE, Potter HD, Azziz R: Prevalence of hyperandrogenemia among non-hirsute oligoovulatory women. Fertil Steril 1999;67:569–572.
17.
Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R: Prevalence of polycystic ovary syndrome in first-degree relations of patients with PCOS. Fertil Steril 2001;75:53–58.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.